Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned with a vengeance. You knew this would happen, yes? To cope, as always, we are quaffing multiple cups of stimulation. Our choice today is Jack Daniels — yes, such a thing exists. Look it up, if you must. Meanwhile, here are some tidbits. Hope your day is simply smashing and do keep us in mind when you run across anything fascinating …

Novartis (NVS) promised to take “fast and decisive action” should an investigation into alleged bribery in Greece find that its managers engaged in unethical or illegal conduct, Reuters writes. The drug maker is in the midst of a bribery probe in which Greek prosecutors in early 2017 raided its offices in Athens. Meanwhile, Switzerland’s Federal Office of Justice confirmed receiving two requests for legal assistance from Greece and the United States concerning probes into Novartis and alleged bribes the drug maker paid to Greek doctors and public officials, Ekathimerini says.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy